Age-related macular degeneration
Findings Suggest Underdiagnosis of AMD Not Uncommon
Approximately 25 percent of eyes deemed to be normal based on dilated eye examination by a primary eye care ophthalmologist or optometrist had macular characteristics that indicated age-related macular degeneration (AMD), according to a study published IN APRIL 2017 by JAMA Ophthalmology.
A release from the publishers explains that approximately 14 million Americans have AMD and, as the baby boomer population ages, this public health problem is expected to worsen. Age-related macular degeneration is the leading cause of irreversible vision impairment in older adults in the United States, yet little is known about whether AMD is appropriately diagnosed in primary eye care. David C. Neely, M.D., of the University of Alabama at Birmingham, and colleagues conducted a study that included 644 people 60 years or older with normal macular health per medical record based on their most recent dilated comprehensive eye examination by a primary eye care ophthalmologist or optometrist. Presence of AMD was based on imaging (color fundus photography).
The sample consisted of 1,288 eyes from 644 participants (average age, 69 years) seen by 31 primary eye care ophthalmologists or optometrists. A total of 968 eyes (75 percent) had no AMD, in agreement with their medical record; 320 (25 percent) had AMD despite no diagnosis of AMD in the medical record. Among eyes with undiagnosed AMD, 78 percent had small deposits under the retina (called drusen), 78 percent had intermediate drusen and 30 percent had large drusen. Undiagnosed AMD was associated with older patient age, male sex and less than a high school education. Prevalence of undiagnosed AMD was not different for ophthalmologists and optometrists.
The authors note that the eyes with undiagnosed AMD that had AMD with large drusen would have been treatable with nutritional supplements had it been diagnosed.
The study noted some limitations.
“The reasons underlying AMD underdiagnosis in primary eye care remain unclear. As treatments for the earliest stages of AMD are developed in the coming years, correct identification of AMD in primary eye care will be critical for routing patients to treatment as soon as possible so that the disease can be treated in its earliest phases and central vision loss avoided.”